Abbott announced plans to separate its Nutrition business into a standalone, publicly traded company by the end of 2027. The new Nutrition company will focus on the growing healthy nutrition market with $8.5 billion in annual sales and iconic brands like Similac and Ensure. Abbott will retain its core healthcare businesses, including medical devices and diagnostics, with about $42 billion in sales. The separation aims to allow both companies to pursue distinct growth strategies and better allocate resources, benefiting shareholders through a tax-free distribution of shares.
Abbott Laboratories (ABT) shares are trading at USD 98.50 on Pluang as of Oct 21, 2026 18:42 WIB, down 4.09% in one day. The stock's market capitalization stands at $177.28 billion, reflecting its significant presence in the healthcare sector. Investor interest remains strong with 67% of Pluang orders being buys, despite the recent price dip.
Abbott Laboratories reported Q3 2026 results with adjusted earnings per share of $1.42, matching estimates, and revenue of $13.01 billion, slightly above expectations. Despite 14.5% sales growth, the company lowered its 2026 sales growth forecast due...
Abbott posted a 14.5% increase in reported sales and 7.0% comparable sales growth for Q3 2026, with GAAP diluted EPS of $0.53 and adjusted EPS of $1.42. The company expanded its portfolio with FDA approvals for innovative products like the Libre Duo ...
